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Abstract
Objective: Glucocorticoids (GCs) serve a variety of important functions throughout the body. The
synthesis and secretion of GCs are under the strict influence of the hypothalamo–pituitary–adrenal
axis. The mechanisms of action of GCs are mediated by the intracellular glucocorticoid receptor (GR).
Over the years, many studies have been performed concerning the regulation of GR expression by GC
concentrations.
Methods: In the present study, we determined the characteristics of the GR in peripheral mononuclear
blood leukocytes (PBML) from thirteen patients with endogenous Cushing’s syndrome and fifteen
control subjects, using a whole cell dexamethasone binding assay. Furthermore, cortisol concentra-
tions were determined in order to investigate a possible relationship between serum cortisol levels and
receptor characteristics.
Results: There were no differences in mean receptor number between patients and controls. On the
other hand, a significantly lower ligand affinity was identified in cells from patients with Cushing’s
syndrome compared with controls. A complete normalisation of the ligand affinity was observed after
treatment in the only patient tested in this respect, whereas the receptor number was not affected. In
patients, there was a statistically significant negative correlation between cortisol concentrations and
ligand affinity, which was not found in controls.
Conclusion: Receptor down-regulation does not occur in PBML from patients with endogenous
Cushing’s syndrome. On the other hand, there seems to be a diminished ligand affinity which possibly
reflects receptor modification in response to exposure to the continuously high cortisol levels in
patients with Cushing’s syndrome. This assumption is substantiated by the fact that in one patient a
normalisation of the ligand affinity after complete remission of the disease was seen.
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Introduction
Glucocorticoids (GCs) serve a variety of important
functions throughout the body. GCs affect metabolism
by maintaining plasma glucose levels. They are
important in the regulation of fat metabolism, mediate
stress response, influence the immune and central
nervous system and have numerous effects on develop-
ment and differentiation (1). The regulation of serum
GC concentrations is under the influence of the
hypothalamo–pituitary–adrenal axis (HPA-axis) (2).
Hypothalamic corticotrophin releasing hormone
(CRH) is transported to the pituitary which, in response,
secretes corticotrophin (ACTH) into the hypophysial
portal system. The adrenal gland is stimulated by ACTH
to synthesise and secrete cortisol. Cortisol, in its turn,
exerts a negative feedback on both the hypothalamic
and the pituitary level in order to complete a negative
feedback loop. In this way, a perfect balance between
cortisol requirement and cortisol secretion can be
achieved. The HPA-axis is under the influence of
many other systems. In cases of stress, for example,
the HPA-axis is activated, resulting in higher
concentrations of GC (2).
Glucocorticoids exert their effects via the cytoplasmic
glucocorticoid receptor (GR), which is a member of the
family of intracellular steroid hormone receptors to
which receptors for vitamin D, retinoic acid and thyroid
hormone also belong (3, 4). The structural organisation
of the GR is characterised by a short and highly
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conserved cysteine rich central region constituting the
DNA binding domain, a relatively well conserved
carboxy terminal domain which is important for both
hormone binding and translocation, and a poorly
conserved amino terminal region containing the
transactivation domains responsible for gene activation
(5). It is now well established that the ability of GCs to
exert their biological effects requires the presence of a
sufficient amount of intact receptor molecules (4, 6).
There is evidence that GRs undergo down-regulation
after exposure to ligand in vitro, in animals and men (7,
8). This receptor down-regulation is supposed to be an
additional form of negative feedback regulation of GC
action, apart from the regulation of GC serum levels by
the HPA-axis (6). Nevertheless, the mechanisms of
possible receptor down-regulation are poorly under-
stood, and many discrepancies in different studies have
been reported. Moreover, most studies investigating
receptor down-regulation were performed in vitro or,
when performed in vivo, used pharmacological amounts
of GCs. In the present study, we investigated GR
characteristics in patients with endogenous Cushing’s
syndrome. The aim was to identify whether GR down-
regulation in peripheral blood mononuclear leukocytes
(PBML) from these patients with long term hyper-
cortisolism who lack a diurnal rhythm of serum cortisol
concentrations does occur. We found no receptor down-
regulation, but a statistically significant decrease in
ligand affinity for the receptor, which appeared to be
closely related to the serum cortisol concentrations.
Furthermore, the ligand affinity returned to normal in a
patient after successful treatment for Cushing’s disease.
Patients and methods
Patients and control subjects
Thirteen patients, seven females and six males, with
clinical and biochemical Cushing’s syndrome were
included. In all patients, 24-h urinary cortisol excretion
was above the upper limits of normal. Furthermore,
they showed insufficient adrenal cortisol suppression in
the overnight 1 mg dexamethasone suppression test,
and diurnal rhythms of serum cortisol concentrations
were absent in all patients. Nine of the patients had
Cushing’s disease, two had an adrenal cortisol-
producing carcinoma, one had ectopic ACTH secretion
and one had an adrenal cortisol-producing adenoma.
Control subjects were fourteen healthy volunteers,
eight females and six males, without Cushing’s syn-
drome or any other endocrine disorder. None of the
female volunteers was using oral anticonceptive drugs
at the time of investigation.
Peripheral blood mononuclear cells
Blood (40 ml) was drawn into heparinised tubes
between 0800 h and 0900 h by venepuncture. PBMLs
were isolated as described previously (9). The blood was
diluted twofold with saline and layered over Ficoll-
Hypaque (Pharmacia, Uppsala, Sweden). The PBML
enriched interphase was isolated and washed twice with
saline. The final cell pellet was resuspended in 15 ml
RPMI-1640 medium (Gibco Europe, Breda, The Nether-
lands), containing 15 mmol/l Hepes, 10% charcoal-
adsorbed fetal calf serum (Amstelstad/Flow, Zwanen-
burg, The Netherlands), 2 mmol/l glutamine, 100 U/ml
penicillin, 100 mg/ml streptomycin and 1.5 mg/ml
fungizone. The cells were incubated for 30 min at
37 8C in a shaking water bath in order to remove
endogenous cortisol. The cell suspension was centri-
fuged and resuspended in 15 ml medium. This proce-
dure was repeated twice more. Finally, the cells were
resuspended at a density of 2.5–10 · 106 cells per ml in
the medium.
Whole cell dexamethasone binding assay
The whole cell dexamethasone binding assay was
performed as described previously by Molijn et al. (9).
Briefly, incubation was started in a volume of 240 ml
(0.5–2 · 106 cells) containing [3H]dexamethasone at
concentrations of 1.3 to 40 nmol/l without (total
binding) and with (specific binding) a 400-fold excess
of unlabelled dexamethasone. Two tubes without
labelled dexamethasone were incubated under the
same conditions for determination of cell number and
viability at the end of the procedure. The tubes were
incubated during 1 h at 30 8C in a shaking water bath.
The incubation was stopped by the addition of 2 ml cold
saline, followed by centrifugation and two washing
steps. Finally, the cells were resuspended in 250 ml
medium. Radioactivity in 200 ml of this suspension was
counted in a liquid scintillation counter. Specific binding
was calculated by subtracting non-specific binding from
total binding. Receptor number and ligand affinity (Kd)
were calculated from the data using the method of
Scatchard (10).
Cortisol determinations
At the same time as blood was withdrawn for the whole
cell dexamethasone binding assay, extra blood was
withdrawn for cortisol determinations. In the patients,
two more blood samples were taken at 1700 h and
2200 h in order to investigate the circadian rhythm of
cortisol concentrations. Patients were at basal rest
during the day the samples were taken. Serum cortisol
concentrations were determined using RIA kits
obtained from DPC (Los Angeles, CA, USA). Intra- and
interassay variations were below 8.0% and 9.5%
respectively.
Statistical analysis
The results for serum cortisol concentrations, number
of receptors and Kd are reported as means 6 S.E.M. To
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assess the relationships between cortisol concentrations
and number of receptors or Kd, linear regression
analysis was used.
Results
There was a statistically significant higher early
morning serum cortisol concentration in patients with
Cushing’s syndrome compared with controls (Table 1).
Although not all individual patients had early morning
cortisol concentrations above the upper normal level
(800 nmol/l), none of the patients with Cushing’s
syndrome had a diurnal rhythm of serum cortisol
concentrations (data not shown).
Table 1 also shows that there were no differences in
the number of receptors per cell between the two
groups. On the other hand, there was a statistically
significantly higher Kd in the patient group compared
with controls, indicating a lower affinity of the receptor
for its ligand.
As shown in Table 2, neither in the patient group nor
in the control group was there a statistically significant
correlation between number of receptors per cell and
serum cortisol concentrations. On the other hand, as
shown in Fig. 1, there was a significant positive
correlation between Kd and serum cortisol concentra-
tions in patients with Cushing’s disease, which was not
present in the control group.
Figure 2 shows the results of Scatchard analyses of
the GR in one of the patients with pituitary-dependent
Cushing’s disease before and after successful trans-
sphenoidal adenomectomy of the ACTH-secreting
microadenoma. Although the basal morning serum
cortisol concentration after remission was not much
lower than during disease (704 nmol/l vs 510 nmol/l
respectively), the serum cortisol concentrations after
treatment showed a diurnal rhythm, in contrast to
those before treatment. The data in Fig. 2 indicate that
while the treatment did not influence the number of
receptors per cell measured in PBML from this patient,
the ligand affinity did normalise after treatment.
Discussion
To our knowledge, GR down-regulation in patients with
endogenous Cushing’s syndrome has never been
investigated. Therefore, we investigated 13 patients
with endogenous Cushing’s syndrome with respect to
GR characteristics. We found no receptor down-regula-
tion, but a significantly lower ligand affinity in patients
compared with controls. A possible explanation could
be that high concentrations of GC influence the
outcome of the whole cell dexamethasone binding
assay. However, a previous study by our group (9)
especially investigated the effect of exposure to high
cortisol concentrations on the number of receptors and
the ligand affinity in this assay. It was shown that only
3.3% of endogenous cortisol remained specifically
bound to the receptor. Moreover, incubation in the
presence of high doses of cortisol affected both receptor
number (‘down-regulation’) and ligand affinity
(‘decreased affinity’). In contrast, the results from this
study show an isolated lowering in ligand affinity,
without effects on receptor number. In addition, the
absolute cortisol concentrations in the patients with
Cushing’s syndrome were much lower than the
concentrations administered in the in vitro experiments
performed by Molijn et al. (9). Since the lowered ligand
affinity does not seem to be caused by the presence of
cortisol in the whole cell dexamethasone binding assay,
these results possibly reflect receptor modification in
response to the exposure to continuously high cortisol
levels, as present in patients with Cushing’s syndrome
who lack a normal diurnal rhythm of serum cortisol
concentrations. This assumption is substantiated by the
fact that in one patient a normalisation of the ligand
affinity was observed after complete remission of the
disease.
The ability of GCs to act on target tissues requires the
presence of intact and sufficient numbers of GRs (3).
Many studies investigating GR numbers have been
performed, on the basis of the hypothesis that receptor
down-regulation might be an additional form of
negative feedback, protecting against the continued
signal elicited by ligand in cases of hypercorticolism or
other forms of GC excess (6). In several studies, a direct
correlation between GR number and the cell’s sensitiv-
ity to GCs was found (11, 12). Furthermore, a receptor
down-regulation in reaction to GC therapy was demon-
strated in cell cultures and animals, including humans
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Table 1 Differences in serum cortisol concentrations and cortisol
receptor characteristics between patients with Cushing’s syndrome
(n = 13) and control subjects (n = 14).
Cushing Controls
Mean S.E.M. Mean S.E.M. P
Serum cortisol (nmol/l) 822 64.5 382 37.6 <0.001*
Number of receptors 6339 417 6184 211 0.72
per cell
Kd (nmol/l) 17.4 1.9 9.3 0.5 <0.001*
* Statistically significant.
Table 2 Correlations between serum cortisol concentrations
and cortisol receptor characteristics in patients with Cushing’s
syndrome (n = 13) and in control subjects (n = 14).
Cushing Controls
r P r P
Number of receptors per cell 0.12 0.68 0.50 0.07
Kd (nmol/l) 0.59 0.03* ¹0.02 0.95
* Statistically significant.
(7, 8). The possible mechanism of this receptor down-
regulation is poorly understood. There is evidence for an
enhanced receptor degradation (13, 14) in vitro but
nothing is known about accelerated GR turnover in vivo.
Furthermore, many investigations were performed on
GR mRNA expression levels. There is evidence that GC
treatment modulates GR expression in a number of
tissues and cell types, and that down-regulation occurs
at both transcriptional, post-transcriptional and/or post-
translational levels (6, 13, 15). Moreover, most of the
data available at present concern in vitro studies or
results obtained after administration of pharmacological
amounts of exogenous GC.
Little is known about the physiological actions of GC
on receptor number or affinity. An elegant example in
this respect would be the syndrome of generalised GC
resistance. GC resistance is a rare disease, in which an
extreme insensitivity of the target tissues to GC action
leads to a clinical syndrome characterised by signs and
symptoms of secondary overproduction of adrenal
androgens and mineralocorticoids. Up until now, the
molecular basis of the clinical syndrome has been
elucidated in only four kindreds. In three of these four
(16–18), different mutations in the hormone binding
domain of the GR gene were found, while in the fourth
kindred (19) a heterozygous splice site deletion at the 30
boundary of exon 6 of the GR gene appeared to be the
cause of the syndrome. In the latter kindred, the splice
site deletion resulted in an unstable mRNA with only
half the number of receptors on PBMLs as a final result.
In all of these patients, the HPA-axis was set at a higher
level, resulting in higher ACTH and cortisol concentra-
tions. None of these patients showed any signs or
symptoms mimicking an Addisonian clinical picture,
meaning that there was a sufficient compensation of
cortisol concentrations as a result of the increased HPA
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Figure 1 Relationship between serum cortisol
concentrations and Kd in PBMLs in 13 patients
with Cushing’s syndrome (X) and 14 healthy
controls (W).
Figure 2 Whole cell dexamethasone binding assays of PBML in a patient with Cushing’s disease before (O) and after (X) successful
treatment.
activity. In none of the patients was receptor up-
regulation demonstrated, especially not in the patient
with only half the number of receptors as a result of the
splice site deletion in the GR gene. In these cases, it can
be concluded that receptor up-regulation is not an
additional feedback system in cases of relative cortisol
shortage.
On the other hand, one might ask why people treated
with GCs develop Cushing’s syndrome; sufficient recep-
tor down-regulation should protect a patient from
developing side-effects of GC treatment. Nevertheless,
many patients treated with GCs have serious adverse
effects.
It can be concluded that there is no GR down-
regulation in patients with endogenous Cushing’s
syndrome, but that a diminished ligand affinity of yet
unknown cause might partially protect the cells from
the high cortisol levels. An explanation for the
mechanism involved is currently unknown: differences
in receptor chaperoning/recycling might be responsible
for the lower affinity in the absence of a variation in
receptor number. Nevertheless, this protecting mechan-
ism seems to be insufficient, because all patients showed
clinical signs and symptoms of GC excess.
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